Heart Failure after Laboratory Confirmed Influenza Infection (FLU-HF).


Journal

Global heart
ISSN: 2211-8179
Titre abrégé: Glob Heart
Pays: England
ID NLM: 101584391

Informations de publication

Date de publication:
2022
Historique:
received: 28 01 2022
accepted: 10 05 2022
entrez: 15 7 2022
pubmed: 16 7 2022
medline: 19 7 2022
Statut: epublish

Résumé

Influenza has been shown to exacerbate heart failure (HF). Importantly, no study to date has examined the relationship between HF hospitalizations (HFH) with laboratory confirmed influenza infections. This study evaluated the association between laboratory confirmed influenza infection and HFH in the two largest hospitals in Saskatchewan, Canada. We used a retrospective self-controlled case series design to evaluate the association between laboratory-confirmed influenza infection and HFH. We compared the incidence ratio for HFH during the influenza risk interval with the control interval. We defined the influenza risk interval as the seven days after a laboratory confirmed influenza result and the control interval as one year before and after the risk interval. We identified 114 HFH that occurred within one year before and after a positive test result for influenza between April 1, 2010, and April 30, 2018. Of these, 28 (28 admissions per week) occurred during the risk interval and 86 (0.853 admissions per week) occurred during the control interval. The incidence ratio of a HFH during the risk interval as compared with the control interval was 33.53 (95% confidence interval [CI], 21.89 to 51.36). A decline in incidence was observed after day seven; between days 8 to 14 and 14 to 28 incidence ratios was 0.91 (95% CI, 0.13 to 6.52) and 0.91 (95% CI, 0.22 to 3.68) respectively. We have observed a significant association between acute influenza infection and HFH. However, further research with a larger sample size and involving a multicenter setting is warranted. Influenza may contribute and exacerbate heart failure events especially during annual influenza season.Early identification of influenza among patients with heart failure, could lead to earlier treatment with antiviral medication, reduce unnecessary antibiotic use, and tail off the morbidity and mortality.In this study, despite our efficient study design, our sample size was limited to only the two largest hospitals in the province, possibly excluding a significant population in remote areas.

Sections du résumé

Background
Influenza has been shown to exacerbate heart failure (HF). Importantly, no study to date has examined the relationship between HF hospitalizations (HFH) with laboratory confirmed influenza infections. This study evaluated the association between laboratory confirmed influenza infection and HFH in the two largest hospitals in Saskatchewan, Canada.
Methods
We used a retrospective self-controlled case series design to evaluate the association between laboratory-confirmed influenza infection and HFH. We compared the incidence ratio for HFH during the influenza risk interval with the control interval. We defined the influenza risk interval as the seven days after a laboratory confirmed influenza result and the control interval as one year before and after the risk interval.
Results
We identified 114 HFH that occurred within one year before and after a positive test result for influenza between April 1, 2010, and April 30, 2018. Of these, 28 (28 admissions per week) occurred during the risk interval and 86 (0.853 admissions per week) occurred during the control interval. The incidence ratio of a HFH during the risk interval as compared with the control interval was 33.53 (95% confidence interval [CI], 21.89 to 51.36). A decline in incidence was observed after day seven; between days 8 to 14 and 14 to 28 incidence ratios was 0.91 (95% CI, 0.13 to 6.52) and 0.91 (95% CI, 0.22 to 3.68) respectively.
Conclusion
We have observed a significant association between acute influenza infection and HFH. However, further research with a larger sample size and involving a multicenter setting is warranted.
Highlights
Influenza may contribute and exacerbate heart failure events especially during annual influenza season.Early identification of influenza among patients with heart failure, could lead to earlier treatment with antiviral medication, reduce unnecessary antibiotic use, and tail off the morbidity and mortality.In this study, despite our efficient study design, our sample size was limited to only the two largest hospitals in the province, possibly excluding a significant population in remote areas.

Identifiants

pubmed: 35837360
doi: 10.5334/gh.1125
pmc: PMC9231574
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

43

Informations de copyright

Copyright: © 2022 The Author(s).

Déclaration de conflit d'intérêts

The authors have no competing interests to declare.

Références

JACC Heart Fail. 2019 Feb;7(2):118-120
pubmed: 30611719
N Engl J Med. 2018 Jan 25;378(4):345-353
pubmed: 29365305
JACC Heart Fail. 2016 Feb;4(2):159-161
pubmed: 26823117
Lancet Infect Dis. 2009 Oct;9(10):601-10
pubmed: 19778762
BMC Cardiovasc Disord. 2015 Sep 30;15:109
pubmed: 26423142
Eur J Heart Fail. 2016 Aug;18(8):891-975
pubmed: 27207191
JACC Heart Fail. 2016 Feb;4(2):152-158
pubmed: 26746371
Arch Intern Med. 2008 Apr 28;168(8):847-54
pubmed: 18443260
Am J Epidemiol. 2008 Apr 1;167(7):775-85
pubmed: 18230677
Eur Respir J. 2018 Mar 29;51(3):
pubmed: 29563170
Heart Fail Rev. 2017 May;22(3):329-336
pubmed: 28508293
JACC Heart Fail. 2019 Feb;7(2):112-117
pubmed: 30611718
Stat Med. 2006 Aug 15;25(15):2618-31
pubmed: 16372391
Can J Cardiol. 2017 Nov;33(11):1342-1433
pubmed: 29111106
Epidemiol Infect. 2007 May;135(4):574-82
pubmed: 16938140
Circulation. 2001 May 8;103(18):2283-8
pubmed: 11342478
Vaccine. 2018 Jan 4;36(2):202-206
pubmed: 29221893

Auteurs

Phyllis Sin (P)

University of Manitoba, The Max Rady College of Medicine, Winnipeg, MB, CA.

Muhammad Siddiqui (M)

Saskatchewan Health Authority, Research Department, Regina, SK, CA.

Rashell Wozniak (R)

University of Alberta, Edmonton, AB, CA.

Idris Bare (I)

University of Saskatchewan, College of Medicine, Saskatoon, SK, CA.

Jessica Minion (J)

University of Saskatchewan, College of Medicine, Regina, SK, CA.

Stephen Sanche (S)

University of Saskatchewan, College of Medicine, Saskatoon, SK, CA.

Jacob Udell (J)

University of Toronto, Faculty of Medicine, Toronto, ON, CA.

Andrea Lavoie (A)

University of Saskatchewan, College of Medicine, Regina, SK, CA.

Payam Dehghani (P)

University of Saskatchewan, College of Medicine, Regina, SK, CA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH